

2019 Future of Rosacea R&D Pipeline Drugs and Companies- Analysis of Global Rosacea Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

https://marketpublishers.com/r/2887ABF4EDEEN.html

Date: January 2019

Pages: 60

Price: US\$ 2,199.00 (Single User License)

ID: 2887ABF4EDEEN

Abstracts

The global demand for Rosacea treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Rosacea pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Rosacea pipeline companies from advancing their products into Phase 3 or Phase 4.

Rosacea Report Description

The H1 2019 pipeline review report on Rosacea pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Rosacea pipeline compounds.

The Rosacea pipeline guide presents information on all active drugs currently being developed for Rosacea. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Rosacea



pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Rosacea drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Rosacea product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Rosacea pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Rosacea pipeline report includes

An overview of Rosacea disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator,



Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Rosacea pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Rosacea pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Rosacea pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.



Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL ROSACEA PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Rosacea Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Rosacea pipeline, H1- 2019
- 3.5 Mechanism of Action wise Rosacea Pipeline Candidates

4. ACCUITIS ROSACEA PIPELINE DETAILS

- 4.1 Accuitis Business Profile
- 4.2 Accuitis Rosacea Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments



5. ACCUITIS PHARMACEUTICALS INC ROSACEA PIPELINE DETAILS

- 5.1 Accuitis Pharmaceuticals Inc Business Profile
- 5.2 Accuitis Pharmaceuticals Inc Rosacea Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. AFECTA PHARMACEUTICALS INC ROSACEA PIPELINE DETAILS

- 6.1 Afecta Pharmaceuticals Inc Business Profile
- 6.2 Afecta Pharmaceuticals Inc Rosacea Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. AOBIOME LLC ROSACEA PIPELINE DETAILS

- 7.1 AOBiome LLC Business Profile
- 7.2 AOBiome LLC Rosacea Drug Details
 - 7.2.1 Drug Snapshot



- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. BIOPHARMX INC ROSACEA PIPELINE DETAILS

- 8.1 BioPharmX Inc Business Profile
- 8.2 BioPharmX Inc Rosacea Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. CELLIX BIO PVT LTD ROSACEA PIPELINE DETAILS

- 9.1 Cellix Bio Pvt Ltd Business Profile
- 9.2 Cellix Bio Pvt Ltd Rosacea Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 9.2.1.5 Area



- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. CUTANEA LIFE SCIENCES INC ROSACEA PIPELINE DETAILS

- 10.1 Cutanea Life Sciences Inc Business Profile
- 10.2 Cutanea Life Sciences Inc Rosacea Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. DERMATA THERAPEUTICS LLC ROSACEA PIPELINE DETAILS

- 11.1 Dermata Therapeutics LLC Business Profile
- 11.2 Dermata Therapeutics LLC Rosacea Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details



11.7 Latest Drug Developments

12. EMERITI PHARMA AB ROSACEA PIPELINE DETAILS

- 12.1 Emeriti Pharma AB Business Profile
- 12.2 Emeriti Pharma AB Rosacea Drug Details
 - 12.2.1 Drug Snapshot
 - 12.2.1.1 Originator
 - 12.2.1.2 Collaborator/Co-Developer
 - 12.2.1.3 Route of Administration
 - 12.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 12.2.1.5 Area
 - 12.2.1.6 Type of Molecular Entity
- 12.3 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13. FOAMIX PHARMACEUTICALS LTD ROSACEA PIPELINE DETAILS

- 13.1 Foamix Pharmaceuticals Ltd Business Profile
- 13.2 Foamix Pharmaceuticals Ltd Rosacea Drug Details
 - 13.2.1 Drug Snapshot
 - 13.2.1.1 Originator
 - 13.2.1.2 Collaborator/Co-Developer
 - 13.2.1.3 Route of Administration
 - 13.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 13.2.1.5 Area
 - 13.2.1.6 Type of Molecular Entity
- 13.3 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14. HOVIONE ROSACEA PIPELINE DETAILS

14.1 Hovione Business Profile



- 14.2 Hovione Rosacea Drug Details
 - 14.2.1 Drug Snapshot
 - 14.2.1.1 Originator
 - 14.2.1.2 Collaborator/Co-Developer
 - 14.2.1.3 Route of Administration
 - 14.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 14.2.1.5 Area
 - 14.2.1.6 Type of Molecular Entity
- 14.3 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15. MATRISYS BIOSCIENCE INC ROSACEA PIPELINE DETAILS

- 15.1 Matrisys Bioscience Inc Business Profile
- 15.2 Matrisys Bioscience Inc Rosacea Drug Details
 - 15.2.1 Drug Snapshot
 - 15.2.1.1 Originator
 - 15.2.1.2 Collaborator/Co-Developer
 - 15.2.1.3 Route of Administration
 - 15.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 15.2.1.5 Area
 - 15.2.1.6 Type of Molecular Entity
- 15.3 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16. PHI THERAPEUTICS INC ROSACEA PIPELINE DETAILS

- 16.1 PHI Therapeutics Inc Business Profile
- 16.2 PHI Therapeutics Inc Rosacea Drug Details
 - 16.2.1 Drug Snapshot
 - 16.2.1.1 Originator
 - 16.2.1.2 Collaborator/Co-Developer
 - 16.2.1.3 Route of Administration



- 16.2.1.4 Orphan Drug/Fast Track/Special Designation
- 16.2.1.5 Area
- 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. PROMIUS PHARMA LLC ROSACEA PIPELINE DETAILS

- 17.1 Promius Pharma LLC Business Profile
- 17.2 Promius Pharma LLC Rosacea Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. SOL-GEL TECHNOLOGIES LTD ROSACEA PIPELINE DETAILS

- 18.1 Sol-Gel Technologies Ltd Business Profile
- 18.2 Sol-Gel Technologies Ltd Rosacea Drug Details
 - 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration
 - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 18.2.1.5 Area
 - 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status
- 18.4 Drug Overview



- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19. SUNNY PHARMTECH INC ROSACEA PIPELINE DETAILS

- 19.1 Sunny Pharmtech Inc Business Profile
- 19.2 Sunny Pharmtech Inc Rosacea Drug Details
 - 19.2.1 Drug Snapshot
 - 19.2.1.1 Originator
 - 19.2.1.2 Collaborator/Co-Developer
 - 19.2.1.3 Route of Administration
 - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 19.2.1.5 Area
 - 19.2.1.6 Type of Molecular Entity
- 19.3 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20. TWI BIOTECHNOLOGY INC ROSACEA PIPELINE DETAILS

- 20.1 TWi Biotechnology Inc Business Profile
- 20.2 TWi Biotechnology Inc Rosacea Drug Details
 - 20.2.1 Drug Snapshot
 - 20.2.1.1 Originator
 - 20.2.1.2 Collaborator/Co-Developer
 - 20.2.1.3 Route of Administration
 - 20.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 20.2.1.5 Area
 - 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

20. LATEST ROSACEA DRUG PIPELINE DEVELOPMENTS, 2019



21. APPENDIX

- 21.1 About Us
- 21.2 Sources and Methodology
- 21.3 Contact Information



I would like to order

Product name: 2019 Future of Rosacea R&D Pipeline Drugs and Companies- Analysis of Global

Rosacea Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and

Developments

Product link: https://marketpublishers.com/r/2887ABF4EDEEN.html

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2887ABF4EDEEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970